Affibody Medical Partnering

Affibody has a proven track record of developing candidate drugs targeting severe diseases based on its proprietary technology platform. To fully unlock the potential of the platform, Affibody seeks partnerships with leading companies that excel in their therapeutic areas.

Izokibep partnerships

To achieve maximum development speed and rapid future market penetration, the global development of izokibep is being conducted in collaboration with ACELYRIN and Inmagene Biopharmaceuticals.

Complement mediated diseases

Affibody’s partner Rallybio is developing the drug candidate RLYB116 which acts by inhibiting the activation of complement factor 5 (C5) in the complement cascade, which is part of the immune system.

Respiratory diseases

Affibody is collaborating with Chiesi to discover and develop novel Affibody® molecules as innovative treatments for respiratory diseases.

Fibrotic diseases

Affibody’s partner Antaros is developing an Affibody®-based PET tracer, ATH001, to probe the presence of platelet-related growth factor receptor beta (PDGFRβ), which is a marker of ongoing fibrogenesis in tissue. This PET diagnostic program complements our therapeutic programs in immunology.

HER2-positive cancers

To complement Affibody’s proprietary radiopharmaceutical development, Affibody’s partner GE Healthcare is also developing a PET imaging candidate, GE-226, with a view to improve the diagnosis of HER2-positive cancers. GE-226 is a Fluorine-18-labeled PET tracer candidate based on the same HER2 targeting Affibody® molecule as Affibody’s own ABY-025.

To fully unlock the potential of the platform, Affibody seeks partnerships with leading companies that excel in their therapeutic areas

Our partners

ACELYRIN

In 2021, Affibody partnered with ACELYRIN for the development of the company’s most advanced drug candidate, izokibep, for development in several autoimmune diseases where the protein IL-17A plays a foundational role.

ACELYRIN holds worldwide rights to izokibep, except for development and commercialization rights held by Inmagene Biopharmaceuticals in selected Asian countries, including China, Hong Kong, South Korea, and Taiwan, but excluding Japan. Affibody holds commercialization rights in the Nordic countries.

 

Inmagene Biopharmaceuticals

In 2020, Affibody partnered with Inmagene Biopharmaceuticals for the development of the company’s most advanced drug candidate, izokibep, in several autoimmune diseases where the protein IL-17A plays a foundational role.

Inmagene holds development and commercialization rights in selected Asian countries, including China, Hong Kong, South Korea, and Taiwan, but excluding Japan.

 

Rallybio

Affibody’s licensee Rallybio is a US-based biotechnology company founded by industrialists from the global biopharma company Alexion. The company develops therapies aimed at severe and rare diseases in hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. RLYB116 is aimed at treating rare complement mediated diseases.

Chiesi Group

In 2023, Affibody and Chiesi partnered for the development of innovative treatments for respiratory diseases. The agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs. Affibody has retained the option to co-promote in the Nordic region.

GE Healthcare

In 2019, Affibody and GE Healthcare initiated a collaboration to develop and commercialize an Affibody®-based PET imaging tracer with a view to improving the diagnosis of HER2-positive cancers.

Antaros

In 2021, Affibody and Antaros entered into a license agreement to develop novel PET imaging tracers to support drug development decisions, with an initial focus on unmet needs in inflammation, fibrosis, and immunology.

Partnering Contacts

We believe that external collaborations are essential for our success.

Contact us